$RGBP .0275 Friday HOD .0295 - Looking for continuation days 3-5+ of this monster run... It could actually run for weeks with the money behind this move!
Regen BioPharma Inc (OTCMKTS: RGBP) is the new darling of small caps currently making a parabolic run up the charts and quickly establishing itself as a top traded stock in small caps. Currently under heavy accumulation RGBP traded $50 million in dollar volume on Thursday alone on 3.5 billion shares traded and is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars. RGBP is in beast mode right now and is the most talked about small cap stock; a break over $0.0295 and things really start popping here.
Regen and its subsidiary KLS have entered into an agreement with Oncology Pharma, Inc. whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property for the treatment in humans of pancreatic cancer for a term of fifteen years from April 7, 2021. The License IP consists of antigen specific cancer vaccines in which modified mRNA is administered to produce epitopes able to produce an immune response which augments likelihood of successful induction of immunity. An epitope is the part of an antigen that is recognized by the immune system. The Company is currently in the process of updating its filings and preparing outstanding 10Q and 10k reports in order to up list to fully reporting otcqb “pink current” tier.
PictureRegen BioPharma Inc (OTCMKTS: RGBP) is a publicly traded biotechnology company focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6. The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). RGBP owns a valuable patent porfolio.
Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses. The Company’s products include HemaXellerate, a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning. HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS. The United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)
dCellVax Breast Cancer – dCellVax – IND #16200. CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.” Establishment of safety will allow for rapid expansion of patient numbers. Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program.
DiffronC – Myelodysplastic Syndrome Gene Silencing – DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells. Silencing using DiffronC induces differentiation of cancer cells. Initial indication is treatment of myelodysplastic syndrome. Other indications include solid tumors and acute leukemia.
Telomeres & Genomic Integrity: Stem cells and cancer cells have found ways of maintaining their telomeres in a state that prevents senescence. Our research in to the cancer stem cell has given us a molecular pathway that can be manipulated to expand stem cells and maintain telomeres. Telomeres are protective structures at the ends of chromosomes that enable cell divisions. Telomere attrition is involved in aging, cancer and genetic mutations. The Company is developing drugs that modulate telomere maintenance. In pre-clinical development for indications of solid cancers and acute leukemia.
In the CBD space RGBP researchers have determined that combining its lead NR2F6 small molecule agonist with Cannabidiol (CBD) may provide a dynamic therapy for treating inflammatory bowel disease (IBD). Currently, there are a number of pre-clinical and clinical studies being conducted by other companies regarding pain management that suggest potential benefits of CBD. Regen believes that CBD may augment the Company’s small molecule therapies for autoimmune disorders, in this case specifically IBD. IBD is a disease caused by persistent and chronic inflammation of the gastrointestinal tract and is a term that refers to both ulcerative colitis and Crohn’s disease. Current treatments include non-specific immune suppressors such as steroids as well as newer drugs recently approved by the FDA. The IBD market size is estimated at $6.7 billion global and projected to be $7.6 billion by 2023.There are currently no non-steroidal therapies available to IBD sufferers.